BDBM316478 4-((trans-4-(4-chlorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide::US9630929, Example 44::US9630929, Example 84

SMILES Fc1cc(c(F)cc1OC[C@@H]1CNCCC1c1ccc(Cl)cc1)S(=O)(=O)Nc1ncns1

InChI Key InChIKey=OCGIYHGXHMLCPX-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 316478   

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM316478(US9630929, Example 44 | 4-((trans-4-(4-chloropheny...)
Affinity DataIC50: 100nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM316478(US9630929, Example 44 | 4-((trans-4-(4-chloropheny...)
Affinity DataIC50: 3.30nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM316478(US9630929, Example 44 | 4-((trans-4-(4-chloropheny...)
Affinity DataIC50: 100nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
Go to US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM316478(US9630929, Example 44 | 4-((trans-4-(4-chloropheny...)
Affinity DataIC50: 58.8nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM316478(US9630929, Example 44 | 4-((trans-4-(4-chloropheny...)
Affinity DataIC50: 1.00E+4nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM316478(US9630929, Example 44 | 4-((trans-4-(4-chloropheny...)
Affinity DataIC50: 1.00E+4nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM316478(US9630929, Example 44 | 4-((trans-4-(4-chloropheny...)
Affinity DataIC50: 1.00E+4nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Xenon Pharmaceuticals

US Patent
LigandPNGBDBM316478(US9630929, Example 44 | 4-((trans-4-(4-chloropheny...)
Affinity DataIC50: 1.00E+4nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
Go to US Patent